Can a common diabetes drug stop prediabetes in its tracks? early study tests feasibility

NCT ID NCT06828731

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether it's possible to use the diabetes drug empagliflozin in 60 veterans with prediabetes. Participants took the drug or received standard lifestyle advice for 12 weeks. The main goal was to see if people would join and stay in the study, not to prove the drug works. If successful, it could pave the way for larger trials to see if empagliflozin can prevent diabetes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Empagliflozin (a diabetes drug that helps the kidneys remove sugar from the body)
What this could lead to
If this pilot shows it's feasible, it could lead to larger studies testing whether empagliflozin can prevent or delay type 2 diabetes in people with prediabetes.
What could go wrong
This is a very small, early-phase feasibility study with only 60 veterans. It is not designed to prove the drug works for prediabetes, and results may not apply to the general population.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PREDIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Charles George VA Medical Center

    Asheville, North Carolina, 28805, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.